The stock of Epizyme, Inc. (NASDAQ:EPZM) is now priced at $14.37 and the shares are 0.53 points up or 3.83% higher compared to its previous closing price of $13.84. The stock had 1.313 million contracts set over the past session. EPZM shares’ daily volume is compared to its average trading volume at 1.173 million shares. However, it has a float of 79.09 million and although its performance was -2.97% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the EPZM share price recently placing at $13.51 to $14.56. However, some brokerage firms have priced the stock below the average, including one that has called $16.

The shorts are running away from the Epizyme, Inc. stock, with the latest data on short interest released on July 15, 2020, showing that short interest numbers in the EPZM shares have declined. Short interest in the stock represents just 13.61% of its float, but the volume has dropped by -280443. The volume of shorted shares dropped to 10.761 million from 11.042 million shares over the last two weeks. The average intraday trading volume has been 858423 shares, which means that days to cover moved to roughly 12.536061.

In the last trading session, Epizyme, Inc. (NASDAQ:EPZM) dropped by -$0.44 over the week and lost -$1.44 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $27.82. The stock recorded its established 52-week high on 01/21/20.

Since 10/09/19, the stock has traded to a low of $9.73 at 47.61%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 2.03. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.

Looking at current readings, Epizyme, Inc.’s two-week RSI is 43.17. This suggests that the stock is neutral at the moment and that EPZM shares’ price movement remains stable. The stochastic readings are equally revealing at 27.55% meaning the EPZM share price is currently in overbought territory.

The technical chart shows that the EPZM stock will likely settle at between $14.78 and $15.2 per share. However, if the stock dips below $13.73, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $13.1.

Currently, the stock is trading in the red of MACD, with a reading of -0.22. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

Analysts at Oppenheimer cut their recommendation for EPZM from Outperform to Perform in April 01 review. Barclays analysts see the stock as a Overweight with a target price of $33 in a flash note released to investors on March 04 initiating covering the stock. H.C. Wainwright analysts see the stock as Buy. Nonetheless, the analysts revised the share prices up on February 25, placing it at $36 from $25.

The average rating for the EPZM equity is 1.89 and is currently gathering a bullish momentum. Of 9 analysts tracking Epizyme, Inc. polled by Reuters, 2 rated EPZM as a hold. The remaining 7 analysts were split evenly. However, the split wasn’t equal as a majority (7) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.

Elsewhere, the EPZM stock price is 0X ahead of its 12-month Consensus earnings per share estimates.

Zacks Consensus Estimate forecasts that the current-quarter revenues for Epizyme, Inc. (NASDAQ:EPZM) will decrease by about -99.68%, which will see them reach $4.3 million. The company’s full-year revenues are, however, expected to increase by about 25.84%, up from $23.8 million to $29.95 million. EPZM’s expected adjusted earnings should surge almost 15.09% to end up at -$0.61 per share, while for the fiscal year, analysts project the company’s earnings to grow by about 23.83% to record -$2.39/share.